First line osimertinib for the treatment of patients with advanced EGFR-mutant NSCLC

被引：2
|
作者：
Ricciuti, Biagio [1 ]
Chiari, Rita [1 ]
机构：
[1] Univ Perugia, Santa Maria Misericordia Hosp, Dept Med Oncol, Perugia, Italy
来源：
TRANSLATIONAL LUNG CANCER RESEARCH | 2018年 / 7卷
关键词：
CELL LUNG-CANCER; 1ST-LINE TREATMENT; OPEN-LABEL; CHEMOTHERAPY; AZD9291;
D O I：
10.21037/tlcr.2018.03.06
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S127 / S130
页数：4
相关论文
共 50 条
  • [31] Efficacy of Osimertinib Continuation Plus Metronomic Oral Vinorelbine for EGFR-mutant Advanced NSCLC Beyond Limited Progression on Osimertinib
    Li, Meifang
    Lin, Cheng
    Lin, Jinghui
    Chen, Shijie
    Weng, Lihong
    He, Zhiyong
    [J]. ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY, 2023, 23 (19) : 2095 - 2101
  • [32] Landscape of EGFR-dependent and independent mechanisms of osimertinib resistance in EGFR-mutant NSCLC patients.
    Le, Xiuning
    Puri, Sonam
    Negrao, Marcelo Vailati
    Nilsson, Monique B.
    Robichaux, Jacqulyne Ponville
    Boyle, Theresa A.
    Hicks, James Kevin
    Roarty, Emily
    Rinsurongkawong, Waree
    Glisson, Bonnie S.
    Zhangx, Jianjun
    Papadimitrakopoulou, Vassiliki
    Gray, Jhanelle Elaine
    Heymach, John
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [33] A brave NEO world: Neoadjuvant osimertinib in resectable EGFR-mutant NSCLC
    Cortiula, F.
    Naidoo, J.
    [J]. LUNG CANCER, 2023, 181
  • [34] Frontline and Post-Osimertinib Therapy for EGFR-mutant Advanced NSCLC: Treatment Patterns, Outcomes, Healthcare Use and Costs
    Girard, N.
    Besse, B.
    Caro, R. Bernabe
    Goto, K.
    Leighl, N.
    Ohe, Y.
    Sabari, J.
    Lee, S-H.
    Lin, X.
    Schaeffer, M.
    Nair, S.
    Li, T.
    Di Scala, L.
    Potluri, R.
    Mahadevia, P.
    Thayu, M.
    Kim, T. M.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S404 - S405
  • [35] INSIGHT 2: Tepotinib plus osimertinib in patients (pts) with EGFR-mutant NSCLC having acquired resistance to first-line osimertinib due to MET amplification (METamp)
    Smit, E. F.
    Felip, E.
    Karachaliou, N.
    Ellers-Lenz, B.
    Wu, Y-L.
    [J]. ANNALS OF ONCOLOGY, 2020, 31 : S894 - S894
  • [36] Osimertinib Rechallenge With Bevacizumab vs. Chemotherapy Plus Bevacizumab in EGFR-Mutant NSCLC Patients With Osimertinib Resistance
    Cui, Qingli
    Hu, Yanhui
    Cui, Qingan
    Wu, Daoyuan
    Mao, Yuefeng
    Ma, Dongyang
    Liu, Huaimin
    [J]. FRONTIERS IN PHARMACOLOGY, 2022, 12
  • [37] CNS Activity of Ramucirumab in Combination with Osimertinib in Patients with Advanced T790M-Positive EGFR-Mutant NSCLC
    Paz-Ares, L.
    Planchard, D.
    Yang, J. C.
    Lee, K.
    Garrido, P.
    Park, K. K.
    Kim, J.
    Lee, D. H.
    Mao, H.
    Chao, B.
    Yu, H.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S453 - S454
  • [38] Prognostic Value of Sequential Liquid Biopsy (LB) after Osimertinib Among Hispanic Patients with Advanced EGFR-Mutant NSCLC
    Cardona, A.
    Zuluaga, J.
    Rojas, L.
    Arrieta, O.
    Ruiz-Patino, A.
    Rodriguez, J.
    Chamorro, D.
    Corrales, L.
    Martin, C.
    Viola, L.
    Raez, L.
    Vargas, C.
    Otero, J.
    Carranza, H.
    Motta, R.
    Rolfo, C.
    Rossell, R.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S667 - S668
  • [39] Primary tumor consolidative therapy improves the outcomes of patients with advanced EGFR-mutant lung adenocarcinoma treated with first-line osimertinib
    Wu, Jia-Jun
    Tseng, Jeng-Sen
    Zheng, Zhe-Rong
    Chu, Cheng-Hsiang
    Chen, Kun-Chieh
    Lin, Mong-Wei
    Huang, Yen-Hsiang
    Hsu, Kuo-Hsuan
    Yang, Tsung-Ying
    Yu, Sung-Liang
    Chen, Jin-Shing
    Ho, Chao-Chi
    Chang, Gee-Chen
    [J]. THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2024, 16
  • [40] Aumonertinib in EGFR-Mutant NSCLC Patients with Liver Dysfunction after TKI Treatment and NSCLC with Basic Hepatopathy as First-Line Therapy
    Luo, F.
    Liu, Y. Y.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S671 - S672
12345